Research programme: positive allosteric modulators - Proximagen

Drug Profile

Research programme: positive allosteric modulators - Proximagen

Latest Information Update: 08 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Developer Proximagen
  • Class Small molecules
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor modulators; Dopamine D1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cognition disorders; Parkinson's disease

Most Recent Events

  • 03 May 2017 Dopamine D1 positive allosteric modulators are still in preclinical development for Cognition disorders in United Kingdom
  • 26 Apr 2017 Preclinical trials in Parkinson's disease in United Kingdom (unspecified route)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cognition-disorders in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top